Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.

Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC.

Neuro Oncol. 2008 Dec;10(6):981-94. doi: 10.1215/15228517-2008-048. Epub 2008 Jul 29.

2.

Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma.

Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC.

Br J Cancer. 2007 Jul 16;97(2):267-74. Epub 2007 Jun 19.

3.

Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor.

Pang JC, Chang Q, Chung YF, Teo JG, Poon WS, Zhou LF, Kong X, Ng HK.

Hum Pathol. 2005 Jan;36(1):36-43.

PMID:
15712180
4.

Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.

Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, Ellison DW, Clifford SC.

Carcinogenesis. 2004 May;25(5):661-8. Epub 2003 Dec 19.

PMID:
14688019
5.

Epigenetic silencing of the HIC-1 gene in human medulloblastomas.

Waha A, Waha A, Koch A, Meyer-Puttlitz B, Weggen S, Sörensen N, Tonn JC, Albrecht S, Goodyer CG, Berthold F, Wiestler OD, Pietsch T.

J Neuropathol Exp Neurol. 2003 Nov;62(11):1192-201.

PMID:
14656076
6.

CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer.

Mori K, Enokida H, Kagara I, Kawakami K, Chiyomaru T, Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa M.

Int J Oncol. 2009 Jun;34(6):1593-602.

PMID:
19424577
7.

Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility.

Frühwald MC, O'Dorisio MS, Dai Z, Tanner SM, Balster DA, Gao X, Wright FA, Plass C.

Oncogene. 2001 Aug 16;20(36):5033-42.

8.

Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.

Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC.

Cancer Res. 2002 Oct 15;62(20):5906-11.

9.

Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma.

Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, Croul S, Ra YS, Eberhart C, Huang A, Bigner D, Grajkowska W, Van Meter T, Rutka JT, Taylor MD.

Neoplasia. 2010 Jan;12(1):20-7.

10.

SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas.

Waha A, Koch A, Hartmann W, Milde U, Felsberg J, Hübner A, Mikeska T, Goodyer CG, Sörensen N, Lindberg I, Wiestler OD, Pietsch T, Waha A.

Oncogene. 2007 Aug 16;26(38):5662-8. Epub 2007 Mar 5.

PMID:
17334394
11.

[Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].

Frühwald MC, O'Dorisio MS, Smith L, Dai Z, Wright FA, Paulus W, Jürgens H, Plass C.

Klin Padiatr. 2001 Jul-Aug;213(4):197-203. German.

PMID:
11528554
12.

Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma.

Pfister S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A, Kulozik A, Scheurlen W, Radlwimmer B, Lichter P.

Nucleic Acids Res. 2007;35(7):e51. Epub 2007 Mar 7.

13.

Epigenetic changes in pilocytic astrocytomas and medulloblastomas.

Gonzalez-Gomez P, Bello MJ, Lomas J, Arjona D, Alonso ME, Amiñoso C, De Campos JM, Vaquero J, Sarasa JL, Casartelli C, Rey JA.

Int J Mol Med. 2003 May;11(5):655-60.

PMID:
12684707
14.

Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.

Misawa K, Kanazawa T, Misawa Y, Imai A, Endo S, Hakamada K, Mineta H.

Cancer Biomark. 2011-2012;10(3-4):135-44. doi: 10.3233/CBM-2012-0242.

PMID:
22674299
15.
16.

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.

Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R.

PLoS One. 2008 Aug 28;3(8):e3088. doi: 10.1371/journal.pone.0003088.

17.

An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.

Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT.

Cancer Res. 2008 Dec 1;68(23):9945-53. doi: 10.1158/0008-5472.CAN-08-2169.

18.

Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma.

Vibhakar R, Foltz G, Yoon JG, Field L, Lee H, Ryu GY, Pierson J, Davidson B, Madan A.

Neuro Oncol. 2007 Apr;9(2):135-44. Epub 2007 Feb 28.

19.

Deletion and aberrant CpG island methylation of Caspase 8 gene in medulloblastoma.

Gonzalez-Gomez P, Bello MJ, Inda MM, Alonso ME, Arjona D, Amiñoso C, Lopez-Marin I, de Campos JM, Sarasa JL, Castresana JS, Rey JA.

Oncol Rep. 2004 Sep;12(3):663-6.

PMID:
15289853
20.

[Risk stratification in medulloblastoma: screening for molecular markers].

Ebinger M, Senf L, Scheurlen W.

Klin Padiatr. 2006 May-Jun;218(3):139-42. German.

PMID:
16688669

Supplemental Content

Support Center